The country’s sovereign wealth fund and the Russian Direct Investment Fund (RDIF) of the biopharmaceutical division of Bangalore-based Strides Pharma have partnered to produce and supply a minimum of 200 million doses (enough to vaccinate 100 million). People of the Russian Sputnik V vaccine against coronovirus).
According to the joint statement, an agreement was signed between RDIF and Stellis Biopharma under the auspices of Enso Healthcare LLP (part of the Aso Group), RDIF’s coordination partner, for sourcing the Sputnik V vaccine in India.
According to the statement, the parties intend to start supplying the vaccine from the third quarter of calendar 2021. Stillis will also continue to work to provide additional supply volumes beyond the initial agreement with RDIF.
Strides Group founder Arun Kumar said, “We are pleased to partner with RDIF to make an important contribution towards providing a global supply of Sputnik V vaccine which is one of the most commercially available effective vaccines.”
“With an efficacy of 91.6%, the Russian vaccine is one of the best vaccines against coronaviruses in the world. Kirill Dimitrik, CEO of the Russian Valley Investment Fund, said significant vaccine volumes produced jointly with Stellis would help increase access to the vaccine globally.
Sputnik V, the world’s first registered vaccine against the novel coronovirus infection, is now approved for use in more than 50 countries. Sputnik V is a two-dose vaccine that uses two different human adenoviral vectors during vaccination.
.
Leave a Reply